BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) ( www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today a 391% increase in sales for the MicroThermX ® Microwave Ablation System (MicroThermX ®) product line for September 2012, as compared to September 2011. Disposable SynchroWave antennas were a significant portion of these sales, reflecting the success of the Company's fee-per-use equipment rental program and increasing utilization of MicroThermX ® equipment. This is a dramatic increase in sales for MicroThermX ® products and representative of a continuing trend of accelerating MicroThermX ® revenue. MicroThermX ® product sales also grew significantly during the fourth quarter of fiscal year 2012, as compared to the fourth quarter of fiscal year 2011. The MicroThermX ® introduced into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, providing an important ongoing revenue stream. BSD's focus for the past year has been to increase MicroThermX ® revenues by the expansion of the fee-per-use equipment rental program and direct sales support in major U.S. metropolitan areas. These programs are producing very successful results, and the current fiscal year promises to provide continuing growth in revenues from the MicroThermX ® products. About the MicroThermX® Microwave Ablation System The MicroThermX ® Microwave Ablation System is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX ® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX ® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX ® introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX ® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX ® System, which allows BSD to market the MicroThermX ® system in Europe. CE marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX ® to a number of international markets. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.